News | Contrast Media | January 19, 2018

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents

Focus will be on hospital-based products that could benefit from reduced renal toxicity

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity. Through this new, internally-funded program, Ligand intends to advance products toward proof-of-concept, followed by selling or out-licensing them for further development and commercialization. The program will leverage Ligand’s patented Captisol technology, as well as data and intellectual property obtained through its acquisition of Verrow Pharmaceuticals, a privately-held Lenexa, Kansas-based medical invention company that Ligand acquired in January 2018 for $2 million in cash plus earnouts.

Ligand CEO John Higgins explained that contrast agents are an important component of the diagnostic imaging market, however they can be toxic and are known to cause kidney damage in some patients. He added that Captisol is a specialized cyclodextrin that plays a role in protecting kidneys from the damaging effects of these agents. Captisol-enabled (CE) iohexol, marketed as Omnipaque by GE Healthcare, has been shown to prevent nephrotoxicity by more than 50 percent in animal models.1

The company said the initial internal program is focused on a CE formulation of iohexol given the large global market, lack of alternatives and focused development path for use in the cardiovascular imaging setting. The initial CE-iohexol program will focus on partnering-enabling studies, with an estimated $6 million of program spend by Ligand over approximately three years.

For more information: www.ligand.com

References

1. Rowe ES, et al. Journal of Neuroimaging 2016; 26(5):511-8


Related Content

Feature | Cardiac Imaging

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

Home March 05, 2024
Home
News | Cardiac Imaging

PLEASE NOTE: This webinar has been postponed to a later date. A new date will be posted in the coming days. On March 25 ...

Home February 29, 2024
Home
News | Cardiac Imaging

February 28, 2024 — Royal Philips, a global leader in health technology, announced major enhancements to its Image ...

Home February 28, 2024
Home
News | Cardiac Imaging

February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL) may ...

Home February 12, 2024
Home
News | Cardiac Imaging

November 16, 2023 — Cardiovascular diseases rank among the top causes of death across the world, and cardiac ...

Home November 16, 2023
Home
News | Cardiac Imaging

September 21, 2023 — Declines in cardiovascular procedure volumes observed early in the COVID-19 pandemic greatly ...

Home September 21, 2023
Home
News | Cardiac Imaging

July 11, 2023 — Hyperfine, Inc., the groundbreaking medical device company that created the Swoop system, the world’s ...

Home July 11, 2023
Home
Feature | Cardiac Imaging | By Matthew Jay Budoff, MD, FACC, FAHA

Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than ...

Home July 10, 2023
Home
News | Cardiac Imaging

June 29, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Home June 29, 2023
Home
News | Cardiac Imaging

June 26, 2023 — Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited ...

Home June 26, 2023
Home
Subscribe Now